Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Bioeq

Next Previous
Drug Profile

Aflibercept biosimilar - Bioeq

Alternative Names: AHZANTIVE; Baiama; FYB-203

Latest Information Update: 10 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Formycon
  • Developer Bioeq; Formycon; Klinge Biopharma
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Choroidal neovascularisation; Diabetic macular oedema; Diabetic retinopathy; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 02 Oct 2025 Valorum Biologics announces intention to launch Aflibercept biosimilar (FYB 203) in the US in the fourth quarter of 2026.
  • 17 Sep 2025 Aflibercept biosimilar licensed to Horus Pharma in selected countries of Europe including France
  • 25 Jun 2025 Aflibercept biosimilar licensed to Valorum Biologics in the US and Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top